Clinical trial • Phase I • Other

Levonorgestrel for Healthy volunteers

Phase I trial of Levonorgestrel for Healthy volunteers. Randomised, open-label, none/not specified-controlled. 60 participants.

Overview

Trial Therapeutic Area
Other
Trial Disease
Healthy volunteers
Trial Stage
Phase I
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
12-12-2025
First CTIS Authorization Date
27-03-2026

Trial design

Randomised, open-label, none/not specified-controlled Phase I trial across 1 site in Spain.

Randomised
Yes
Open Label
Yes
Comparator
None/Not specified
Target Sample Size
60
Trial Duration For Participant
74

Eligibility

Recruits 60 isVulnerablePopulationSelected: true; no further details on vulnerable population, consent or assent handling provided in the record..

Vulnerable Population
isVulnerablePopulationSelected: true; no further details on vulnerable population, consent or assent handling provided in the record.

Recruitment

Planned Sample Size
60
Recruitment Window Months
2

Geography

Total Number Of Sites
1
Total Number Of Participants
60

Spain

Earliest CTIS Part Ii Submission Date
17-12-2025
Latest Decision Or Authorization Date
27-03-2026
Processing Time Days
100
Number Of Sites
1
Number Of Participants
60

Sites

Site Name
Women Hub Medical Services S.L.
Department Name
Phase I Unit
Contact Person Name
Luciana Bergamaschi
Number Of Participants
60

Sponsor

Primary sponsor

Full Name
Chemo Research S.L.
Organisation Type
Pharmaceutical company
Country Of Registered Address
Spain

Investigational products

Investigational Product Name
Levonorgestrel Vaginal Delivery System
Active Substance
Levonorgestrel
Modality
Small molecule
Routes Of Administration
Vaginal
Route
Vaginal
Frequency
Different days of use

Related trials

Other published trials that may interest you.